Trials / Not Yet Recruiting
Not Yet RecruitingNCT07340788
Amylin-Induced Migraine Attacks Without Aura
Amylin-Induced Migraine Attacks Without Aura: A Randomized Clinical Trial
- Status
- Not Yet Recruiting
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 21 (estimated)
- Sponsor
- Danish Headache Center · Academic / Other
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Not accepted
Summary
Pramlintide is a peptide analogue of human amylin which is a vasoactive signaling molecule involved in the pathogenesis of migraine. This study investigates whether pramlintide induces migraine attacks without aura in people with migraine without aura.
Detailed description
Amylin is a vasoactive substance that acts on vascular smooth muscle and can cause vasodilation. It is naturally present in the trigeminovascular system, an important structure involved in headache development. Recent studies indicate that intravenous infusion of pramlintide, an amylin analogue, can trigger migraine attacks in people with migraine. This study aims to determine whether intravenous pramlintide can induce migraine attacks without aura in individuals who experience migraine without aura. To test this, the investigators will conduct a randomized, double-blind, placebo-controlled, two-way crossover trial.
Conditions
- Headache Disorders, Primary
- Headache Disorders
- Brain Diseases
- Nervous System Diseases
- Central Nervous System Diseases
- Neurologic Manifestations
- Signs and Symptoms
- Pathological Conditions, Signs and Symptoms
- Migraine Disorders
- Headache
- Pain
- Peptide Hormones
- Hormones
- Hormones, Hormone Substitutes, and Hormone Antagonists
- Peptides
- Amino Acids, Peptides, and Proteins
- Amylin
- Pramlintide
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Amylin | The participants will receive continuous intravenous infusion of 20 mL (6 μg/min) of pramlintide (amylin) over 20 minutes. |
| DRUG | Placebo | The participants will receive continuous intravenous infusion of 20 mL of placebo (isotonic saline) over 20 minutes. |
Timeline
- Start date
- 2026-02-01
- Primary completion
- 2028-10-30
- Completion
- 2028-10-30
- First posted
- 2026-01-14
- Last updated
- 2026-01-14
Locations
1 site across 1 country: Denmark
Source: ClinicalTrials.gov record NCT07340788. Inclusion in this directory is not an endorsement.